I suppose the lack of sales people is one of the biggest obstacles to overcome. Although, with the approval of the diabetes therapy from the Chinese FDA last December, the potential market within the country alone would be enormous -- why haven't they partnered up with an entity that has an established sales force? I know the acquisition with Ming Cheng was finalized, but that hasn't appeared to be of much help with getting their products to consumers.
If that one drug alone could be marketed to even a fraction of the beneficial population, this stock would shoot through the roof. Let's hope that AXM employee can forward this message to management ;-)
Jimmie